ART3

ART3 Full Name

ADP-ribosyltransferase 3

ART3 Introduction

ADP-ribosyltransferase 3 (ART3) is a cell-surface glycoprotein belonging to the mono-ADP-ribosyltransferase (ART) family. Classically, enzymes in this family catalyze the transfer of ADP-ribose from NAD+ to specific target proteins, thereby modifying their structural and functional properties. Although early structural analyses suggested that human ART3 might lack canonical catalytic activity due to sequence variations in its active site—often leading to its classification as a pseudocatalytic or purely structural scaffolding protein—recent advanced research has firmly established its role as a critical signaling modulator. Under healthy physiological conditions, the expression of ART3 is highly restricted and specific. It is predominantly expressed in the testis, specifically localizing to the surface of spermatocytes. In this highly specialized microenvironment, ART3 is heavily involved in regulating complex cellular interactions during spermatogenesis and maintaining male reproductive health. Consequently, genetic variants of the ART3 gene have been identified as significant susceptibility factors for male infertility, particularly non-obstructive azoospermia.

Figure 1. ADP-ribosylation by bacterial and mammalian ADP-ribosyltransferases. (Source: Koch-Nolte F, et al. 2006)

Despite its highly restricted expression in healthy adult tissues, the aberrant overexpression of ART3 is increasingly recognized as a potent driver in highly aggressive human malignancies, most notably triple-negative breast cancer (TNBC) and melanoma. TNBC is a notoriously difficult-to-treat breast cancer subtype characterized by the absence of targetable hormone receptors and extreme clinical aggressiveness. Extensive molecular profiling has identified ART3 as a significantly upregulated biomarker in basal-like TNBC tissues. In this malignant context, ART3 functions essentially as an oncogene. Its robust overexpression strongly hyperactivates critical intracellular survival networks, specifically the AKT and ERK signaling cascades. This pathway hyperactivation dramatically enhances tumor cell proliferation, survival, and invasive capacity, leading to poor clinical outcomes.

Similarly, in malignant melanoma—a skin cancer characterized by a high propensity for early and rapid distant metastasis—ART3 is frequently and heavily overexpressed. Experimental silencing of the ART3 gene in melanoma models severely impairs the migratory and invasive capabilities of the cancer cells, fundamentally suppressing their metastatic potential. Because ART3 exhibits such stark differential expression—remaining nearly absent in most normal tissues but robustly overexpressed in deadly, chemoresistant solid tumors—it presents a highly attractive, tumor-specific vulnerability. Consequently, ART3 is rapidly transitioning from an enigmatic germline protein into a compelling prognostic biomarker and a highly promising target for the development of novel antibody-drug conjugates (ADCs) and targeted oncological therapies.

Alternate Names for ART3

ART3; ADP-ribosyltransferase 3; ecto-ADP-ribosyltransferase 3; mono-ADP-ribosyltransferase; mono(ADP-ribosyl)transferase 3; NAD(P)(+)--arginine ADP-ribosyltransferase 3; FLJ26404;

• 1. Koch-Nolte F, et al. ADP-ribosylation of membrane proteins: unveiling the secrets of a crucial regulatory mechanism in mammalian cells. Ann Med. 2006;38(3):188-99.
  2. Tan L, et al. ART3 regulates triple-negative breast cancer cell function via activation of Akt and ERK pathways. Oncotarget. 2016 Jul 19;7(29):46589-46602.